Introduction 59
Chronic kidney disease (CKD) is estimated to affect up to 6% of women of child bearing age 60 in high income countries (1). Frequently, antenatal visits are the first time women are 61 assessed by health care, thus providing an opportunity to identify CKD. However, few 62 studies have investigated the aetiology of renal disease identified during or after pregnancy, 63 and to our knowledge none have compared with the spectrum of disease in non-pregnant 64 women. Improved understanding of renal pathologies identified during pregnancy will inform 65 decision making about the necessity of biopsy during or after pregnancy. 66
Pregnancy is a 'stress test' for the kidney and may lead to progression of pre-existing 67 disease. It is possible that less severe disease may be revealed during pregnancy but there 68 is limited study of natural history of renal disease identified during or after pregnancy to 69 guide long term prognosis and management of young women with newly diagnosed CKD. 70
Our aims were to define the aetiologies and long-term outcomes of renal disease identified 71 during pregnancy or within one-year postpartum, and compare these with non-pregnant 72 women of child-bearing age. 73 74
Materials and Methods 75
All renal biopsy reports for women of child-bearing age (16 to <50yrs) from five renal units 76 serving 21 referring hospitals (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) were reviewed. The clinical details of the reason 77 for biopsy were assessed, and pathology records interrogated. Women who were biopsied 78 for abnormal urinalysis / raised serum creatinine (SCr) identified during pregnancy 79 (regardless of the timing of the subsequent biopsy), and all women biopsied within one year 80 postpartum were included in the pregnancy-related diagnosis group. Repeat and inadequate 81 biopsies were excluded. Protein: Creatinine Ratio (PCR) was recorded where available, and 82 quantification in g/24hr was converted to an estimated PCR by multiplying by 100. Albumin: 83
Creatinine Ratio (ACR) quantification were excluded from analyses as they could not be 84 reliably converted to an estimated PCR. 85 formula (2). Women of mixed race that included black heritage were categorised as black. 87
Women who were on RRT during follow-up were considered to have eGFR of 10ml/min per 88
1.73m
2 for the purpose of calculating change in renal function over time. In view of the 89 expected physiological fall in serum creatinine (SCr) during pregnancy, for the purpose of 90 assessing eGFR and rate of change in eGFR, comparison was made between controls and 91 post-pregnancy patients only i.e. women biopsied during pregnancy were not included in this 92 analysis due to inaccuracies of GFR estimates in pregnancy (3, 4) . 93
Each biopsy was assigned a primary diagnosis, and additional concurrent diagnoses 94 recorded. If focal segmental glomerulosclerosis (FSGS) was present but deemed to be 95 secondary to an alternative intrinsic renal pathology, cases were categorised according to 96 the primary diagnosis and not FSGS. All pregnancy-related biopsies and all indeterminate 97 cases (including in the control group) were re-reviewed by two histopathologists 98 independently with consensus agreement for diagnosis. All FSGS biopsies (pregnancy-99 related and controls) were formally classified according to Columbia classification (5). For 100 the remaining controls, the biopsy diagnosis in the original report was used. 101
Results

115
1399 biopsies were identified in women aged between 16-50 years, including 173 116 pregnancy-related biopsies (19 antenatal, 154 post-pregnancy) and 1226 control biopsies, 117 between 1997 and 2012. One thousand control women were matched for age and ethnicity, 118
and included all women with equal ages and ethnicities as the pregnancy-related group i.e. 119 women were not excluded if there was more than one match per pregnancy-related case. 120 Figure 1 shows how the matched cohorts were assembled, and the baseline demographics 121 are shown in Table 1 . The median age of women with a pregnancy-related diagnosis was 122 significantly lower than controls, and there was a higher proportion of women of 'black or 123 black British' ethnicity in the pregnancy-related group compared to controls. SCr at the time 124 of biopsy was significantly lower in the pregnancy-related group. There was no difference in 125 urinary PCR between women with biopsies performed post-pregnancy and controls, but 126 PCR in women with biopsies performed antenatally was significantly higher than those 127 performed after delivery (p=0.02), and compared to controls (p=0.02). 128
129
Histological diagnoses 130
Focal segmental glomerulosclerosis (FSGS) was the primary diagnosis in 32.4% (56/173) of 131 pregnancy-related biopsies compared to 9.7% (97/1000) of controls (p<0.001). Lupus 132 nephritis (LN) was found more commonly in controls (23.5% (235/1000) vs 13.9% (24/173), 133 p=0.001) ( Table 2) . 134
Women with pregnancy-related FSGS were younger than controls but there were no 135 significant differences in ethnicity or Colombia classification between groups. Creatinine at 136 time of biopsy was significantly lower in the pregnancy-related group. (Table 3 ). There were 137 no disagreements between histopathologists in diagnoses or Columbia Classifications. 138
139
Renal outcomes 140
time from delivery to biopsy was 199 days (IQR 92, 312) , including nine biopsies performed 142 within six weeks. Follow-up data on renal function were available for 58.4% (101/173) of the 143 pregnancy-related group and 45.9% (459/1000) of the control group (Table 3) . There was no 144 difference in the median follow-up time between pregnancy-related and control groups. 145
Women with a pregnancy-related diagnosis (excluding those diagnosed antenatally), were 146 more likely to have an overall decline in eGFR in the follow-up period than matched controls 147 despite adjustment for remaining differences in age and ethnicity between groups (odds ratio 148 1.67, 95% CI 1.03-2.71, p=0.04). This decline also appeared to be more rapid in the 149 pregnancy-related group (-1.33 vs -0.56ml/min per 1.73m 2 per year respectively; p=0.045). 150
There was no correlation between age and rate of decline in eGFR (Spearman's Rho=0.03, 151 n=546, p=0.53). There were no significant differences between the proportion of women 152 requiring RRT between pregnancy-related cases and controls or deaths during the follow-up 153 period (Table 4) . 154
There were no significant differences in rate of change in eGFR in women with FSGS 155 between groups, or requirement for RRT or death (Table 5) . 156
157
Comparison between antenatal and postpartum biopsies 158
Median SCr was similar, and urinary PCR higher, at the time of biopsy in women biopsied 159 antenatally compared to those biopsied post-pregnancy (table 1). There were no differences 160 in biopsy diagnoses between groups (table 2) and no difference in those that died or 161 required RRT (table 3) . 162
163
Discussion 164
Main findings 165
This study demonstrates the wide range of glomerular diseases identified by renal biopsy 166 during or within one year of pregnancy, supporting the role of renal biopsy for confirmation of 167 diagnosis in this patient group. FSGS was more frequently reported in pregnancy-relatedbiopsies than in controls, but no differences in Colombia classification were observed. 169
Conversely lupus nephritis was less commonly identified during or after pregnancy than in 170 controls. Women with a pregnancy-related diagnosis had lower SCr concentrations at time of 171 biopsy than controls, thus pregnancy may provide an opportunity to identify CKD at earlier 172 stages. Women with biopsies after pregnancy also had a more rapid decline of eGFR during 173 follow-up than controls, despite comparable severity of proteinuria, highlighting the 174 importance of detection and diagnosis of renal disease revealed by pregnancy. Nearly one in 175 forty women (2.3%) with a pregnancy-related renal biopsy died and one in eight (12.7%) 176 required RRT during the follow-up period. This emphasises the severity of a diagnosis of 177 glomerular disease in young women, and the substantial implications it has for the individual 178 and her new family. 179
180
Strengths and weaknesses 181
To our knowledge, this is the largest study of pregnancy and post-pregnancy biopsies with 182 secondary histological classification, and the only study to include controls with matching for 183 age and ethnicity. Data were from 21 referring centres hence unlikely to be confounded by 184 centre specific subjective decision making about indications for biopsy. However, the study 185 is unable to address the long-term renal outcomes of other renal diseases identified within 186 one year of pregnancy that do not require biopsy for diagnosis e.g. reflux nephropathy or 187 cystic kidney disease, thus these data relate only to glomerular disease. One of the 188 limitations of our study was the absence of detailed pregnancy data (including parity and 189 diagnosis of pre-eclampsia) hence it was not possible to establish the relationship between 190 pregnancy outcomes and renal biopsy lesions. Furthermore, due to the large number of 191 centres included it was not possible to confirm that all control women had not had a recent 192 pregnancy which was not reported on the biopsy request form. We acknowledge also that Unlike animal micropuncture studies (11) which report unchanged intraglomerular pressure 205 during pregnancy, a recent systematic review, using synthesised estimations from formal 206 assessment of renal plasma flow and glomerular filtration rate (GFR), described an increase 207 in filtration fraction in healthy pregnancy (12), thus further exacerbation of haemodynamic 208 changes could contribute to the development of FSGS in pre-eclampsia. However, the 209 proportion of biopsies with the perihilar variant of FSGS, which is the typical pattern of 210 adaptive FSGS in non-pregnant patients (13), was not greater in pregnancy-related cases 211 than control groups in our study, although true discrepancies may not have been identified 212 by the small numbers within classification subgroups. 213
More recently podocyte loss has been proposed to lead to progressive renal injury in women 214 with pre-eclampsia. Podocyturia is reported in women with pre-eclampsia, prior to, at time of 215 diagnosis and postpartum (14 -16) and downregulation of podocyte-specific proteins (e.g. 216 nephrin, synaptopodin and GLEPP-1) is reported in the renal biopsies of women with 217 preeclampsia (17, 18). Similarly, podocyturia is observed in patients with FSGS (19) and 218 with progression of other glomerular diseases (20). However, there is a regression of 219 histological findings of pre-eclampsia, including complete resolution of 'FSGS-like lesions' 220 after delivery in historic large biopsy series (10, 21). Furthermore, detailed renal 221 physiological assessment of 57 women with pre-eclampsia observed that functional 222 manifestations of glomerular endothelial injury were undetectable after four weeks (22), 223
suggesting that immediate pathophysiological changes secondary to pre-eclampsia may not9 be contributory to persistent renal abnormalities in the postpartum period, and that pre-225 existing renal injury may be important. For example, one in five women with severe pre-226 eclampsia had underlying renal disease in a biopsy series of 86 women (23) and a wide 227 range of renal pathologies were reported in a population study of renal biopsies performed in 228 pregnancies complicated by pre-eclampsia (24). Moreover, Norwegian population studies 229 have identified pre-eclampsia in a previous pregnancy to be associated with increased 230 relative risk of having a future renal biopsy (24), and developing future ESRD (25) but the 231 risk of progression to ESRD in women with renal biopsies remote from pregnancy is not 232
augmented by a history of previous pre-eclampsia (26) . 233 234
Other histological diagnoses 235
Higher rates of LN were observed in the renal biopsies of the control group compared to 236 women in the pregnancy-related group. A recent systematic review reported an estimated 237 rate of 16.1% (95% CI 9.0-23.2%) lupus nephritis flare during pregnancy (27). However, Day 238 et al reported LN to be present in 35% and 8% of biopsies performed in pregnancy and 239 postpartum respectively (6). The lower incidence of LN diagnosed within one year of 240 pregnancy in this study may reflect more women with SLE conceiving with quiescent disease 241 or differences in local practice. For example, due to perceived risks of renal biopsy during 242 pregnancy, some physicians may treat women who develop LN empirically without biopsy. 243
244
Progression of CKD 245
In this study, women with a pregnancy-related diagnosis had lower SCr at time of biopsy 246 than controls, even after exclusion of antenatal biopsies and adjustment for age. Pregnancy 247 is associated with a 50% increase in glomerular filtration thus is a 'stress test' for the kidney 248 (28) , and may provide an opportunity to detect early disease. Our study also identified a 249 more rapid decline in GFR in women with renal disease identified within one year of 250 pregnancy despite comparable levels of proteinuria, less severe disease at diagnosis, and 251 adjustment for age and ethnicity. The National Institute of Clinical Health Excellence (NICE) recommend that the absolute risk of renal disease after hypertensive complications in 253 pregnancy is low and no specific advice or follow-up is required (29), and there are no 254 specific recommendations regarding follow-up of renal disease identified during pregnancy. 255 NICE guidelines recommend that 24-hour urine collection remains the gold standard of 256 analysis of proteinuria in pregnancy; however spot urine PCR is an acceptable alternative 257 therefore both methods were included. There is insufficient evidence on the use of ACR in 258 pregnancy (29, 30) and therefore they were not included in the analysis. The CKD-EPI 259 formula may underestimate GFR in pregnant women (2, 31) hence cases with antenatal 260 biopsies were not included in analyses of renal function. Nine of the postpartum group were 261 biopsied within six weeks of delivery, and a persistent pregnancy related elevation in eGFR 262 may have influenced findings, although this effect is likely to be minimal. It is also possible 263 that nephrology led follow-up of only women with more severe disease diagnosed during or 264 after pregnancy may confound analysis of progression of renal disease, although the 265 inclusion of five renal centres in this study reduces the influence of individual centre policy 266 on selection of women who continued to have nephrological follow-up. The rate of ESRD 267 (12.7%) in women with a pregnancy-related diagnosis was not higher than controls, but 268 appears to be lower than a smaller study of 53 women with proteinuria identified in 269 pregnancy performed over two decades ago (21% progressed to ESRD) (32). In contrast, 270
Day et al reported much higher rates of women developing ESRD (30%) after women 271 biopsied antenatally which may reflect differences in thresholds for biopsy or length of follow-272 up. The high rate of progression of renal disease identified during pregnancy suggests that 273 earlier intervention and nephrology follow-up, even for those with less severe disease, is 274
warranted. 275 276
Indications and safety of biopsy 277
Due to the large number of centres included we were unable to obtain detailed clinical 278 information following the biopsy which is a limitation of this study. Thus we are unable to 279 compare risk of biopsy during or after pregnancy with controls. The decision to perform arenal biopsy during pregnancy is complex for both the clinician and mother. However, our 281 data and others support the role of renal biopsy either during or after pregnancy as 282 histological confirmation is likely to lead to a change in management in the majority of 283 women (33). 284
285
Conclusions 286
The findings of this study support the use of renal biopsy as a diagnostic tool for the 287 investigation of renal disease identified during or within one year of pregnancy. Pregnancy 288 provides an opportunity for detection of disease and thus prevention of CKD progression and 289 of future cardiovascular disease. FSGS is more commonly found in women who have been 290 pregnant than in controls and furthermore, women with a pregnancy-related diagnosis have 291 a more rapid progression of disease. Further work is required to determine whether 292 pregnancy initiates, exacerbates or reveals renal disease. 
